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The human immunodeficiency virus (HIV) Tat protein is acetylated by the transcriptional coactivator p300, a necessary
step in Tat-mediated transactivation. We report here that Tat is deacetylated by human sirtuin 1 (SIRT1), a
nicotinamide adenine dinucleotide-dependent class III protein deacetylase in vitro and in vivo. Tat and SIRT1
coimmunoprecipitate and synergistically activate the HIV promoter. Conversely, knockdown of SIRT1 via small
interfering RNAs or treatment with a novel small molecule inhibitor of the SIRT1 deacetylase activity inhibit Tat-
mediated transactivation of the HIV long terminal repeat. Tat transactivation is defective in SIRT1-null mouse
embryonic fibroblasts and can be rescued by expression of SIRT1. These results support a model in which cycles of Tat
acetylation and deacetylation regulate HIV transcription. SIRT1 recycles Tat to its unacetylated form and acts as a
transcriptional coactivator during Tat transactivation.
Citation: Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, et al. (2005) SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 3(2): e41.
Introduction
The Tat protein of human immunodeficiency virus 1 (HIV-
1) is essential for the transcriptional activation of the
integrated HIV-1 provirus. Without Tat, HIV transcriptional
elongation is inefficient and results in abortive transcripts
that cannot support viral replication [1,2]. Tat is produced
early after infection from rare full-length genomic transcripts
generated despite the elongation defect. These transcripts
lead to the synthesis of a few Tat molecules sufficient to
stimulate HIV transcription elongation, leading to the
production of additional Tat transcripts and protein.
Tat activates HIV transcription through the trans-acting
responsive element (TAR), an RNA stem-loop structure that
forms at the 59 end of all viral transcripts [3,4]. The TAR stem
contains a three-nucleotide bulge structure recognized by the
arginine-rich motif (ARM) in Tat (amino acids 49–57). In vivo,
Tat binding to TAR requires cyclinT1, a cofactor that
interacts cooperatively with both the N-terminal transactiva-
tion region of Tat (amino acid 1–48) and loop sequences at
the top of the TAR stem-loop structure [5]. CyclinT1, a
component of pTEFb (the positive transcription elongation
factor b), recruits the cyclin-dependent kinase 9 (CDK9) to
the HIV promoter. CDK9 hyperphosphorylates the C-termi-
nal domain of RNA polymerase II, which potently enhances
the processivity of the RNA polymerase II complex [6].
We and others have shown that Tat is acetylated at lysine 50
by the transcriptional coactivators p300 and human GCN5
(general control of amino acid synthesis 5) [7,8,9,10]. Tat
acetylation is important for Tat activity and defines a critical
cyclinT1-independent step in Tat transactivation [11]. Tat
acetylated at lysine 50 cannot form a ternary complex with
cyclinT1 and TAR RNA. It dissociates from TAR and binds
instead to the p300/CREB-binding protein-associated factor
(PCAF) via its bromodomain [12,13].
Our current working model is that Tat acetylation disrupts
the Tat/TAR/cyclinT1 complex and leads to the transfer of
Tat and PCAF to the elongating polymerase. According to
this model, both forms of Tat, unacetylated and acetylated,
play distinct roles in the HIV promoter transcriptional cycle
and lead to the sequential recruitment of the cofactors
cyclinT1 and PCAF. Because of the limiting amounts of Tat
protein in the early stages of HIV infection and the critical
role of unacetylated Tat for pTEFb recruitment to TAR, the
question arises whether Tat acetylation can be reverted via a
cellular Tat deacetylase.
There are three distinct classes of human histone deace-
tylases (HDACs) based on their homology with yeast tran-
scriptional repressors. Class I and II HDACs are homologous
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to the yeast proteins Rpd3p (reduced potassium dependency
3) and Hda1p (histone deacetylase A1), respectively [14,15].
The deacetylase activity of class I and II HDACs is efficiently
inhibited by trichostatin A (TSA) and other related hydro-
xamate-based inhibitors.
Class III HDACs, also named sirtuins (SIRTs), are homo-
logous to the yeast transcriptional repressor silent informa-
tion regulator 2p (Sir2p) [16]. Sir2p is a TSA-insensitive
histone deacetylase that requires nicotinamide adenine
dinucleotide (NADþ) as a cofactor [17,18,19]. Seven homologs
of Sir2p have been identified in the human genome. Called
SIRT1–7, they all contain a highly conserved catalytic domain
[20]. Despite their enzymatic activity on histone substrates in
vitro, recent experimental evidence suggests that SIRT
proteins predominantly target nonhistone proteins for
deacetylation, in both the nucleus and the cytoplasm. The
nuclear SIRT1 protein deacetylates p53 [21,22,23], TAFI68
(Tata box-binding protein-associated factor I of 68 kDa) [24],
PCAF and myoblast determination protein (MyoD) [25], p300
[26] and Forkhead transcription factors [26,27], the p65
subunit of nuclear factor kappa B (NF-jB) [28], and the Ku70
telomeric protein (also known as the thyroid autoantigen of
70 kDa or Ku antigen) [29]. The cytoplasmic SIRT2 protein is
found associated with the microtubule network and deacety-
lates lysine 40 of a-tubulin [30]. SIRT3 is a mitochondrial
matrix protein whose target has not been identified [31,32].
Here, we identify the class III HDAC SIRT1 as a specific Tat
deacetylase and demonstrate that SIRT1 is a novel cofactor
necessary for efficient Tat-mediated transactivation of the
HIV promoter.
Results
To test the ability of SIRT1–7 to deacetylate Tat in vitro, we
transfected HEK 293 cells with expression vectors for human
SIRT1–7 and immunoprecipitated the FLAG-tagged proteins
(Figure 1A). The immunoprecipitated material was incubated
with a full-length synthetic Tat protein carrying an acetylated
lysine at position 50 (AcTat). The extent of Tat deacetylation
was determined by Western blot (WB) with antibodies specific
for the acetylated ARM in Tat [11]. Incubation of AcTat with
immunoprecipitated SIRT1, SIRT2, and SIRT3 resulted in
deacetylation of Tat lysine 50 (Figure 1B). These enzymes also
deacetylate histones as determined in a standard histone
deacetylase assay (Figure 1B). All reactions contained equal
amounts of AcTat as determined by immunoblotting with
streptavidin-horseradish peroxidase conjugate (SA-HRP),
which recognized the biotin label attached to the N terminus
of AcTat (SA-HRP in Figure 1B). SIRT enzymes in the
reactions were visualized by immunoblotting with FLAG
antibodies (FLAG in Figure 1B).
SIRT2 and SIRT3 proteins are localized primarily in the
cytoplasm and the mitochondria [30,31], and SIRT1 resides in
the cell nucleus [23,33]. Since Tat is a predominantly nuclear
protein, we focused our efforts on SIRT1. The SIRT1-
Figure 1. In Vitro Tat Deacetylation by Human SIRT Proteins
(A) Scheme of Tat deacetylation assay with immunoprecipitated SIRT1–7 proteins. Expression vectors for FLAG-tagged SIRT proteins were
transfected into HEK 293 cells, immunoprecipitated, and incubated with synthetic Tat (72 amino acids) carrying an N-terminal biotin label and
an acetyl group at position 50 (AcTat) in the presence of NADþ. Immunoprecipitated material was also analyzed in a radioactive (3H) histone
deacetylase assay using an H3 peptide as a substrate.
(B) WB analysis of deacetylation reactions with antibodies specific for acetylated lysine 50 in Tat (a-AcTat), with SA-HRP, or with a-FLAG
antibodies.
(C) WB of Tat deacetylation by immunoprecipitated SIRT1 in the presence or absence of NADþ, TSA, or nicotinamide (Nic).
DOI: 10.1371/journal.pbio.0030041.g001
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mediated deacetylation of Tat was dependent on NADþ and
completely inhibited by nicotinamide, an inhibitor for class
III HDACs [34,35]. TSA, a specific inhibitor of class I and II
HDACs, had no effect (Figure 1C). These results demonstrate
that the Tat deacetylase activity within immunoprecipitated
SIRT1 material can be solely attributed to SIRT1 and not to a
contaminating class I or II HDAC.
To test whether Tat and SIRT1 interact, Tat/FLAG and
SIRT1/influenza hemagglutinin (HA) were overexpressed in
HEK 293 cells, and cellular lysates subjected to coimmuno-
precipitation assays. Tat was detected with an a-FLAG
antiserum in material immunoprecipitated with SIRT1 by
the a-HA antibody in cells transfected with SIRT1- and Tat
expression vectors, but no signal was obtained when SIRT1 or
Tat alone was expressed (IP: a-HA in Figure 2A). Conversely,
SIRT1 also specifically coimmunoprecipitated with Tat/FLAG
(IP: a-FLAG in Figure 2A). The same was observed when Tat/
T7 was coexpressed with SIRT1/FLAG and was immunopre-
cipitated with a-T7 antibodies (Figure 2B). No coimmuno-
precipitation of Tat was observed with SIRT2 and SIRT6
(Figure 2B), two SIRT proteins that can also localize to the
cell nucleus (BN and EV, personal communication), or any
other SIRT protein (unpublished data). Furthermore, Tat
coimmunoprecipitated with endogenous SIRT1 in Tat-ex-
pressing, but not in vector-transfected, HEK 293 cells (Figure
2C). No SIRT1- or Tat-specific signals were obtained after
immunoprecipitations (IPs) in the absence of a-SIRT1 anti-
bodies, excluding nonspecific binding of Tat to the Sepharose
beads to which the antibodies were bound.
To test whether Tat and SIRT1 interact directly, increasing
amounts of biotinylated synthetic Tat (72 amino acids) were
incubated with recombinant full-length SIRT1. After pull-
down with streptavidin-conjugated agarose, SIRT1 coimmu-
noprecipitated with Tat in a dose-dependent manner (Figure
2D). Recombinant SIRT1 bound equally well to acetylated
and unacetylated synthetic Tat, indicating that the inter-
action occurred independently of the acetylation state of Tat
(Figure 2D). WB with AcTat antibodies showed that AcTat
remained acetylated during incubation with the SIRT1
enzyme (Figure 2D). Re-blotting with SA-HRP detected both
Tat proteins in equivalent amounts in the binding reactions
(Figure 2D). We also tested the ability of a Tat mutant protein
Figure 2. Physical Interaction between Tat and SIRT1
(A) Immunoprecipitation (IP) and WB of FLAG-tagged Tat (Tat-FLAG) and HA-tagged SIRT1 (SIRT1-HA) after transfection of corresponding
expression vectors (þ) or empty vector controls () into HEK 293 cells.
(B) The same experiments as in (A) performed with T7-tagged Tat and FLAG-tagged SIRT1, SIRT2, and SIRT6.
(C) Coimmunoprecipitation of FLAG-tagged Tat with endogenous SIRT1 in HEK 293 cells transfected with the Tat expression vector or the
empty vector control. IPs were performed with or without rabbit a-SIRT1 antibodies.
(D) WB of recombinant SIRT1 protein after pulldown with synthetic biotinylated Tat or AcTat. Tat proteins were detected with antibodies
specific for acetylated lysine 50 in the Tat ARM (a-AcTat) or SA-HRP.
(E) Immunoprecipitation/WB of FLAG-tagged Tat or TatK50R and HA-tagged SIRT1. WT, wild type.
DOI: 10.1371/journal.pbio.0030041.g002
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(termed TatK50R to indicate mutation of lysine to arginine
at position 50 of the Tat protein) to interact with SIRT1. This
mutation preserves the basic charge at position 50, but
cannot be acetylated. After transfection into HEK 293 cells,
TatK50R accumulated to lower concentrations than wild-
type Tat, but was bound to SIRT1 efficiently in coimmuno-
precipitation assays (Figure 2E). These results collectively
indicate that Tat binds SIRT1 directly and independently of
lysine 50.
The effects of SIRT1 on Tat function were assessed after
transfection into HeLa cells. SIRT1 modestly, but reprodu-
cibly, enhanced Tat-mediated transactivation of an HIV
promoter luciferase construct (HIV LTR in Figure 3A). In
contrast, expression of a catalytically inactive SIRT1 protein
(termed SIRT1H363Y to indicate mutation of histidine to
tyrosine at position 363 of the SIRT1 protein) suppressed Tat
transactivation in a dominant-negative manner, indicating
that the catalytic activity of SIRT1 is necessary for Tat
transactivation. Similar results were obtained when an HIV
promoter reporter construct containing mutant binding sites
for the transcription factor NF-jB was used (HIV LTR DNF-
jB in Figure 3A). This result indicates that the super-
induction of Tat activity by wild-type SIRT1 and the
suppression of Tat activity by catalytically inactive SIRT1
were dependent on the interaction between SIRT1 and Tat
rather than on the interaction between SIRT1 and NF-jB/p65
[28]. Importantly, SIRT1 (both wild-type and SIRT1H363Y
mutant) had no effect on the transcriptional activity of the
Rous sarcoma virus (RSV) LTR, a promoter used to drive Tat
expression in these cotransfection experiments.
Figure 3. SIRT1 Is a Positive Cofactor for Tat Transactivation
(A) Cotransfection of SIRT1 or the catalytically inactive SIRT1 mutant SIRT1H363Y with the HIV LTR luciferase construct and increasing
amounts of a Tat expression vector (RSV-Tat: 0, 2, 20, and 200 ng), an HIV LTR luciferase construct containing mutated binding sites for the
transcription factor NF-jB and RSV-Tat (20 ng), or with an RSV-luciferase construct (200 ng) in HeLa cells. The average of three experiments is
shown (6 standard error of the mean [SEM]).
(B) WB analysis of HeLa cells 72 h after transfection of siRNAs directed against SIRT1 or GL3 control siRNAs.
(C) Cotransfection of the HIV LTR luciferase construct with increasing amounts of CMV-Tat or CMV-TatK50R (0, 50, 100, 200, 400, and 800 ng) 48
h after transfection of double-stranded siRNAs directed against SIRT1 or GL3 control siRNAs in HeLa cells. Luciferase activity was measured 24 h
after plasmid transfection and 72 h after siRNA transfection. Note that all luciferase reporter vectors used in this study are based on the pGL2
luciferase vector, which is not affected by GL3-specific siRNAs [36]. The average of three experiments is shown (6 SEM).
(D) The transcriptional activity of increasing amounts of the CMV-luciferase reporter (0, 50, 100, 200, 400, and 800 ng) was similar in SIRT1
knockdown or GL3-treated control cells. The average of two experiments performed in duplicate is shown (6 SEM).
(E) WB of endogenous SIRT1 or actin 72 h after transfection of siRNA directed against SIRT1 or mutated SIRT1 siRNA.
(F) Cotransfection of the HIV LTR luciferase with increasing amounts of CMV-Tat (0, 2, 20, and 200 ng) in HeLa cells pretransfected with wild-
type or mutant SIRT1 siRNA oligonucleotides as described in (C). WT, wild-type.
DOI: 10.1371/journal.pbio.0030041.g003
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The effect of SIRT1 on Tat transactivation was further
examined using small interfering RNA (siRNA)-mediated
knockdown of SIRT1. HeLa cells were transfected with
double-stranded RNA oligonucleotides directed against
SIRT1 or against firefly luciferase expressed from the pGL3
vector as a control. All luciferase reporter constructs
described in this study are based on the pGL2 vector, which
is not affected by GL3 siRNAs (siRNAs directed against firefly
luciferase expressed from the pGL3 vector) [36]. Levels of
endogenous SIRT1 were markedly reduced at 72 h after
Figure 4. Impaired Tat Transcriptional Activity in Murine SIRT1/ Cells
(A) Nuclear microinjection of HIV LTR luciferase, RSV-Tat, and a human cyclinT1-expressing construct into MEFs derived from SIRTþ/þ or
SIRT/mice. In all experiments, a fixed amount of DNA was injected by adding the empty vector control. Cells were coinjected with CMV-GFP,
and the luciferase activity per GFP-positive cell was calculated. An average of two injections is shown.
(B) The HIV LTR luciferase construct together with RSV-Tat and the cyclinT1-expressing construct were coinjected into SIRT/ MEFs in the
presence of increasing amounts of a plasmid expressing human SIRT1. The average of three experiments is shown (6 SEM).
(C) Coinjection of the human SIRT1 expression vector together with the 5xUAS luciferase construct containing five Gal4 binding sites upstream
of the thymidine kinase promoter and a Gal4-VP16 expression plasmid into SIRT1/MEFs. The average of three experiments is shown (6 SEM).
DOI: 10.1371/journal.pbio.0030041.g004
Figure 5. Transcriptional Activity of AcTat Depends on Deacetylation by SIRT1
(A) AcTat functions through TAR and cyclinT1 binding. Nuclear microinjection of increasing amounts of synthetic Tat or AcTat together with
wild-type (wt TAR), TAR Dbulge, or TAR Dloop mutant HIV LTR luciferase constructs into HeLa cells. Cells were coinjected with CMV-GFP, and
luciferase activity was calculated per GFP-positive cell. An average of three experiments is shown (6 SEM).
(B) AcTat transactivation requires CDK9. HeLa cells microinjected with Tat or AcTat (each 30 ng/ll) and the HIV LTR luciferase reporter were
treated with increasing amounts of DRB, a known CDK9 inhibitor, for 4 h.
(C) AcTat transcriptional activity is inhibited by nicotinamide, but not TSA. HeLa cells injected with HIV LTR luciferase and increasing amounts
of AcTat were treated with TSA (400 nM) or nicotinamide (5 mM) for 4 h. The average of two experiments is shown.
(D) SIRT1 is necessary for AcTat, but not Tat function. HeLa cells were transfected with siRNAs specific for SIRT1 or GL3 control siRNAs 48 h
before microinjection of HIV LTR luciferase and Tat or AcTat (each 30 ng/ll). The average of three experiments is shown (6 SEM).
DOI: 10.1371/journal.pbio.0030041.g005
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transfection of siRNAs specific for SIRT1 (Figure 3B). At that
time, a significant decrease in Tat transactivation was noted
in cells that had received the SIRT1 siRNA, but not the GL3
siRNA (Figure 3C). The SIRT1 siRNA slightly enhanced the
basal HIV promoter activity without Tat, and had no effect
on the transcriptional activity of TatK50R, the Tat mutant
that cannot be acetylated (Figure 3C). Loss of SIRT1 had no
effect on the transcriptional activity of the immediate early
promoter of the cytomegalovirus (CMV) used to drive Tat
expression in these experiments (Figure 3D). In addition, Tat
levels in HeLa cells transfected with SIRT1 siRNAs were
comparable to Tat levels detected in cells transfected with
GL3 siRNAs as determined by WB (unpublished data). To
confirm the specificity of the SIRT1 siRNA, mutant double-
stranded siRNA oligonucleotides were generated which
contained a two-nucleotide mismatch between the target
mRNA for SIRT1 and the antisense strand of the siRNA.
Transfection of mutant SIRT1 siRNA did not affect expres-
sion of endogenous SIRT1 protein in HeLa cells, indicating
that the mutation abrogated SIRT1 mRNA cleavage (Figure
3E). SIRT1 siRNA, but not mutant siRNA, suppressed Tat
transactivation of the HIV LTR luciferase construct, con-
firming that the observed suppression was dependent on the
loss of SIRT1 protein (Figure 3F).
Since SIRT1 only modestly enhanced Tat transactivation in
HeLa cells, which already express significant levels of SIRT1,
we examined the effect of SIRT1 on Tat transactivation in a
SIRT1-negative background. We obtained mouse embryonic
fibroblasts (MEFs) derived from SIRT1 knockout mice [37].
The HIV LTR luciferase reporter and the Tat expression
vector were introduced into these cells by nuclear micro-
injections because of their low responsiveness to various
transfection protocols. Because murine cyclinT1 does not
support Tat transactivation [38,39], an expression vector for
human cyclinT1 was included in the microinjections. A 120-
fold increase in HIV promoter luciferase activity was detected
in the presence of Tat and human cyclinT1 in SIRT1þ/þMEFs
(Figure 4A). In contrast, Tat-mediated transactivation of the
HIV LTR was reduced in SIRT1/MEFs (Figure 4A). Ectopic
expression of increasing amounts of human SIRT1 resulted in
a dose-dependent increase of Tat transactivation in SIRT1/
MEFs (Figure 4B). In contrast, transactivation of the 5xUAS
promoter by Gal4-VP16 was reduced in response to SIRT1
(Gal4-VP16 is a fusion between the binding domain of the
DNA-binding transcription factor required for the activation
of the GAL genes in response to galactose in Saccharomyces
cerevisiae [termed Gal4], and the activator domain of the
herpes simplex virus transactivator protein [designated
VP16]) (Figure 4C). These results collectively demonstrate
that SIRT1 represents a positive factor for Tat function.
This model was further tested in nuclear microinjection
experiments using synthetic full-length Tat and AcTat.
Microinjection of increasing amounts of either Tat or AcTat
proteins into HeLa cells caused a marked transactivation of
the HIV LTR luciferase reporter in a dose-dependent manner
(Wt TAR in Figure 5A). AcTat transactivated the HIV
promoter approximately 1.5–3-fold better than Tat. Trans-
activation by Tat and AcTat was dependent on the bulge and
loop regions of TAR, indicating that transactivation by both
proteins required the formation of an intact Tat/TAR/
cyclinT1 complex [4,5,40] (TAR DBulge and TAR DLoop in
Figure 5A). In agreement with this conclusion, transactivation
Figure 6. Inhibition of HIV Gene Expression by a Small Molecule Inhibitor of SIRT1
(A) In vitro histone deacetylation assays including recombinant SIRT1, radioactively labeled histone H3 peptide, and indicated concentrations of
splitomicin or HR73. The average (6 SEM) of two experiments performed in duplicate is shown for each point.
(B) Chemical structures of splitomicin and its derivative HR73.
(C) Inhibition of Tat transactivation by HR73. RSV-Tat (0, 20, and 200 ng) and HIV LTR luciferase (200 ng) or RSV-luciferase (200 ng) vectors
were transfected into HeLa cells. Transfected cells were treated with indicated concentrations of HR73 or DMSO for 8 h.
(D) Inhibition of HIV gene expression by HR73. GFP expression in Jurkat T cells infected with HIVNL4–3 containing the GFP open reading frame
in place of the viral nef gene or with an HIV-based lentiviral vector expressing GFP from the heterologous EF-1a promoter. Treatment with
HR73 (1 lM in DMSO) or DMSO was performed for 36 h after overnight infection. The average (6 SEM) of four experiments is shown.
DOI: 10.1371/journal.pbio.0030041.g006
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by both Tat proteins was inhibited in a dose-dependent
manner by 5,6-dichlorobenzimidazole riboside (DRB), a
CDK9 inhibitor known to block Tat function (Figure 5B) [6].
According to our working model, AcTat represents a
second step in the transactivation cycle [11]. Since AcTat
cannot form the trimolecular complex with cyclinT1 and
TAR RNA in vitro, we hypothesized that AcTat becomes
partially deacetylated by the Tat deacetylase upon micro-
injection. This would allow the initiation of the trans-
activation process by unacetylated Tat binding to TAR with
cyclinT1 and CDK9. To further test this hypothesis, we
treated cells with deacetylase inhibitors after microinjection
of AcTat and the HIV promoter construct. Treatment with
TSA, an inhibitor of class I and II HDACs, enhanced the
transcriptional activity of AcTat as well as the basal HIV
promoter activity (TSA in Figure 5C). In contrast, nicotina-
mide, an inhibitor of class III deacetylases, blocked trans-
activation of the HIV promoter by AcTat while stimulating
basal HIV promoter activity (Nicotinamide in Figure 5C).
Similarly, knockdown of SIRT1 using siRNA inhibited tran-
scriptional activity of AcTat, while slightly enhancing Tat-
mediated or basal transcriptional activity of the HIV
promoter (Figure 5D). These results support the model that
the transcriptional activity of AcTat depends on deacetyla-
tion by SIRT1 in cells.
The identification of SIRT1 as an enzyme that catalyzes an
important step in HIV transcription suggests that it could be
targeted therapeutically. Splitomicin was identified as a small
molecule inhibitor of the S. cerevisiae Sir2p protein [41]. While
splitomicin did not inhibit human SIRT1, we identified a
splitomicin derivative, called HR73, which is structurally
related to a previously described inhibitor of Hst1, a homolog
of Sir2p in yeast [42]. HR73 effectively inhibited the histone
deacetylase activity of SIRT1 in vitro with an IC50 (concen-
tration causing 50% inhibition) of less than 5 lM (Figure 6A
and 6B). Treatment of HeLa cells with HR73 suppressed Tat-
dependent HIV transcription in a dose-dependent manner
(3-fold at approximately 1 lM) after transfection of the Tat
vector and the HIV LTR luciferase construct (HIV LTR in
Figure 6C). In separate experiments, HR73 induced hyper-
acetylation of another target of SIRT1, the tumor suppressor
p53, at the same concentration (1 lM) (Wei Gu and EV,
unpublished data). Importantly, HR73 (1 lM) did not
suppress the activity of the RSV LTR, the promoter driving
Tat expression in our experiments (RSV LTR in Figure 6C).
To examine the effect of HR73 on HIV infection, we
generated infectious HIV particles using a molecular clone of
HIVNL4–3 that contained the green fluorescent protein (GFP)
open reading frame in place of the viral nef gene (HIVNL4–3 is
a specific viral isolate) [43]. To restrict analysis to a single
infection cycle, this clone also contained a frameshift
mutation in the viral env gene. Viral particles were produced
by cotransfection with a construct expressing the glycopro-
tein of the vesicular stomatitis virus (VSV-G). Jurkat T cells
were incubated with viral supernatant for at least 18 h,
washed to remove extracellular virus, and treated with HR73
(1 lM) or dimethyl sulfoxide (DMSO), as a control. We
observed that HIV gene expression was reduced 5-fold in cells
treated with HR73 as measured by GFP expression (HIV GFP
in Figure 6D). In contrast, GFP expression in cells infected
with an HIV-based lentiviral vector expressing GFP from the
elongation factor 1a (EF-1a) promoter was not affected by
HR73 treatment (HIV [EF-1a] in Figure 6D). These data
confirm the selectivity of HR73 for HIV transcription and
demonstrate that other steps in the viral life cycle, including
reverse transcription, nuclear import, and integration,
remain unaffected by HR73. These experiments collectively
show that the SIRT1 deacetylase activity is required for HIV
gene expression and establish SIRT1 as a potential drug
target in the treatment of HIV-1 infection.
Discussion
Our previous work documented that Tat acetylation by
p300 at lysine 50 is a necessary step in Tat-mediated
transactivation and leads to the recruitment of PCAF to the
elongating polymerase. We now report the identification of
SIRT1, an NADþ-dependent class III protein deacetylase, as a
Tat deacetylase and regulator of Tat activity. Tat and SIRT1
coimmunoprecipitate and synergize to activate the HIV
promoter. Conversely, knockdown of SIRT1 via siRNA
inhibits Tat-mediated transactivation of the HIV LTR. Tat
transactivation is defective in SIRT1-null MEFs and can be
rescued by expression of SIRT1.
Recent observations indicate that SIRT1 can regulate
transcription via histone-dependent and -independent mech-
anisms [20]. Since SIRT1 itself does not bind to DNA directly,
targeted deacetylation of histones is thought to occur
through its interaction with specific DNA binding factors,
such as CTIP2 (chicken ovalbumin upstream promoter-
transcription factor-interacting protein 2) [44], members of
the hairy-related basic helix-loop-helix repressors (HES1
[hairy and Enhancer-of-split 1] and HEY2 [hairy and
Enhancer-of-split related with YRPW motif 2]) [45], the
MyoD/PCAF complex [25], and the N-CoR (nuclear receptor
co-repressor) and SMRT (silencing mediator of retinoid and
thyroid hormone receptor) co-repressors [46]. In addition,
SIRT1 binds and deacetylates histone H1 and promotes the
formation of facultative heterochromatin [33].
SIRT1 also deacetylates nonhistone factors, including the
tumor suppressor p53 [21,22,23]. Detailed studies of acetyla-
tion of p53 and its regulation by SIRT1 have revealed a
number of intriguing parallels to Tat regulation. p53 is
acetylated by p300 at multiple lysine residues, including
lysine 382, leading to an increased transcriptional activity of
p53 [47]. Activation of p53 up-regulates the expression of
genes whose products promote cell-cycle exit or apoptosis
[22]. Therefore, p300 is a positive regulator of p53 activity,
while SIRT1 negatively regulates p53 functions. SIRT1
deacetylation of p53 suppresses the induction of apoptosis
and promotes cell survival in response to DNA damage
[21,22]. Knockout mice for Sir2a show increased p53
acetylation after DNA damage leading to increased thymo-
cyte apoptosis after ionizing radiation [48]. Interestingly,
both SIRT1 and p53, and the Tat cofactor cyclinT1, are
localized in promyelocytic leukemia protein bodies [23,49].
These unique nuclear substructures represent the natural
accumulation sites of promyelocytic leukemia protein and
are altered or disrupted in certain tumors and in response to
different cellular stresses, including Tat expression (EV,
unpublished data).
Interestingly, HDAC1 (a class I HDAC) has also been
reported to deacetylate p53 [50], but the relative contribu-
tions of both HDAC1 and SIRT1 to p53 deacetylation remain
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unclear. In a previous study, an enhancement of Tat-
mediated transactivation was observed in response to TSA,
an inhibitor of class I and II HDACs, and was interpreted as
evidence that Tat acetylation is under the control of a class I
or II HDAC [7]. However, a positive effect of TSA on Tat-
mediated transactivation can occur for a number of reasons
that are independent of Tat acetylation levels. First, the HIV
promoter can be activated by TSA in the absence of Tat, a
phenomenon likely to be mediated by transcription factors
responsive to TSA that bind to the HIV LTR, such as Sp1
(stimulatory protein 1), YY1 (Yin Yang 1), Eed (embryonic
ectoderm development protein), and NF-jB/p65 [51,52,53].
Tat-independent activation of the HIV LTR by TSA has been
documented both in vitro using chromatinized templates,
and in vivo using cell lines containing integrated HIV
genomes defective for Tat-mediated transactivation
[54,55,56]. Second, TSA activates many promoters that are
used to drive Tat expression in transient transfection
experiments, making interpretations of these experiments
problematic.
We have observed that Tat acetylation at lysine 50 is not
specifically enhanced in response to TSA [11]. These results
are supported by functional experiments with Tat mutants.
In cotransfection experiments, enhanced transcriptional
activity of Tat in response to TSA is preserved when lysine
50 is replaced by an alanine [7] or an arginine (MO,
unpublished data). Although these experiments are compli-
cated by the significant increase in Tat expression (due to the
stimulatory role of TSA on Tat expression), they provide
evidence that lysine 50 in fact might not be a target for a
TSA-sensitive enzyme in HIV transcription.
Another system that offers intriguing parallels to our
observation is the role of the SIRT1/MyoD/PCAF complex in
myogenesis [25]. In this complex, PCAF acetylates both itself
and MyoD. SIRT1, in contrast, deacetylates both PCAF and
MyoD, leading to a retardation of myogenesis. The negative
effect of SIRT1 in the regulation of muscle gene expression
plays at two distinct levels. First, SIRT1 induces deacetylation
of histones in the promoter regions. Second, SIRT1 deace-
tylates MyoD, which leads to an inhibition of its transcrip-
tional activity [57]. Our previous experiments documented
the specific interaction of acetylated Tat and PCAF via the
PCAF bromodomain and the ARM region of Tat and the role
of this interaction in Tat transactivation [13]. The possibility
that Tat bound to the elongating polymerase and to PCAF is
regulated by a PCAF-SIRT1 complex is intriguing and will be
further explored.
In most identified sites of action, SIRT1 showed a negative
activity on transcriptional regulatory mechanisms, resulting
in an inhibition of target gene expression. In contrast, we
have identified a positive regulatory activity of SIRT1 on Tat-
mediated transactivation. According to our working model,
Tat becomes acetylated at the level of the HIV promoter after
binding to TAR. The acetylation of the Tat ARM can
potentially affect other biological activities associated with
this domain, including RNA binding, nuclear or nucleolar
import, and protein stability. Tat acetylation could also be
involved in the delivery of Tat to the transcription complex,
and/or might moderate interactions with cyclinT1/CDK9
prior to transcription. However, we provided evidence that
Tat acetylation leads to a dissociation of Tat from cyclinT1
and TAR and to its transfer to the elongating polymerase [11].
Acetylated Tat, bound to the elongating polymerase, recruits
the transcriptional coactivator PCAF via its acetyl group and
the bromodomain of PCAF [12,13].
An unresolved question raised by this model is the fate of
acetylated Tat at the end of the transcription cycle. Since
acetylated Tat cannot recruit cyclinT1 to the TAR element, a
new transcription cycle would require either the synthesis of
a new unacetylated Tat protein or the deacetylation of Tat.
Tat concentrations are limiting early in the virus life cycle
since Tat expression is under the control of the basal LTR.
Tat recycling is therefore likely to represent a rate-limiting
step in HIV transcription early during the replicative cycle of
the virus. Experiments presented in this manuscript demon-
strate that SIRT1 catalyzes this rate-limiting step in HIV
transcription.
These observations raise a number of additional questions.
The demonstration that Tat transactivating activity is
controlled by SIRT1 connects HIV transcription with the
metabolic state of the cell. The HDAC activity of SIRT1
requires NADþ as a cofactor. NADþ and its reduced form
NADH serve as cofactors in many metabolic and stress
reactions involving oxidation and reduction. Changes in the
cellular NADþ/NADH ratio may regulate SIRT1 enzymatic
activity, Tat transcriptional activity, and HIV replication and
pathogenesis.
The site of Tat deacetylation is unknown at this point. We
hypothesize that the deacetylation could be triggered by
molecular events linked with the end of the transcriptional
elongation process. Deacetylation of Tat by SIRT1 could lead
to its dissociation from the elongating polymerase and from
PCAF. The previous demonstration that PCAF and SIRT1 can
be coimmunoprecipitated from cells supports this model [25].
The identification of SIRT1 as an enzyme that catalyzes a
rate-limiting step in HIV transcription suggests that it could
be targeted therapeutically. Since our preliminary experi-
ments indicated that splitomicin, an inhibitor of the S.
cerevisiae Sir2 enzymatic activity, did not inhibit the mamma-
lian sirtuins, we screened several compounds structurally
related to splitomicin for their ability to inhibit the
mammalian sirtuins. This process led to the identification
of HR73, an inhibitor that suppresses SIRT1 enzymatic
activity in vitro at low micromolar concentrations. This
inhibitor induced p53 hyperacetylation in vivo (unpublished
data) and significantly decreased HIV transcription. These
results validate SIRT1 as a novel therapeutic target for HIV
infection. Future efforts will analyze in additional molecular
detail the role of Tat acetylation and deacetylation in HIV
transcription and replication.
Materials and Methods
Cells and plasmids. HeLa, HEK 293, and Jurkat cells (obtained
from the American Type Culture Collection, Manassas, Virginia,
United States), and wild-type or Sir2a knockout MEFs [37] were
maintained under standard cell culture conditions. The HIV LTR
luciferase plasmid [58], the RSV LTR luciferase construct [11], the
5xUAS luciferase construct [59], the LTRDNF-jB-luciferase, the full-
length (101 amino acid) CMV-Tat/FLAG and CMV-Tat/T7 expression
vectors [8], the full-length (101 amino acid) RSV-Tat expression
vector [60], the full-length cyclinT1 expression vector [5], the Gal4-
VP16 expression vector [13], the human SIRT1–7 expression vectors
with a C-terminal FLAG tag [30], as well as wild-type and mutant
human SIRT1 and SIRT1H363Y containing a C-terminal MYC
(myelocytomatosis oncogene) tag [23] were previously described.
The SIRT1 cDNA was subcloned to generate a C-terminal HA-
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tagged fusion in a derivative pcDNA 3.1 (þ) backbone (HA vector) by
standard PCR-based strategies. The mutant CMV-Tat/FLAG expres-
sion vector TatK50R was generated by site-directed mutagenesis with
the following primers. Forward, 59-CCTATGGCAGGAGGAAGCGGA-
GACAGCG-39 and reverse, 59-CGCTGTCTCCGCTTCCTCCTGCCA-
TAGG-39. The mutant HIV LTR luciferase constructs (nucleotides 1–
791) were generated by site-directed mutagenesis with the following
primers. TAR Dbulge (T223fiA) forward, 59-GGTTAGACCAGAACT-
GAGCCTGGGAGC-3 9 and reverse , 5 9-GCTCCCAGGCT-
CAGTTCTGGTCTAACC-39. The TAR Dloop mutation (C230fiA,
T231fiG, and G234fiT) was generated with the following primers.
Forward, 59-GGTTAGACCAGATCTGAGCAGGGTAGCTCTCTGGC-
TAACTAGGG-39 and reverse, 59-CCCTAGTTAGCCAGAGAGC-
TACCCTGCTCAGATCTGGTCTAACC-39.
The CMV-luciferase construct was generated by cloning the firefly
luciferase gene as a HindIII/BamHI fragment obtained from pGL2
Basic (Promega, Madison, Wisconsin, United States) into pcDNA3.1
(Invitrogen, Carlsbad, California, United States). The CMV-GFP
expression plasmid is commercially available (Clontech, Palo Alto,
California, United States).
Synthesis of Tat and HR73. Synthesis of 72-amino acid Tat
proteins was as described [11,13]. HR73 was synthesized starting from
Phenylmeldrum’s acid and 6-bromo-1-dimethylaminomethyl-2-naph-
thol as described [61]. Identity and purity were assured by mass,
infrared, and NMR spectroscopy as well as by elemental analysis.
In vitro Tat deacetylation assay. Human SIRT1–7 FLAG-tagged
plasmids were transfected in HEK 293 cells with Lipofectamine
reagent (Invitrogen). Cells were lysed 24 h after transfection with lysis
buffer (50 mM Tris-HCl [pH 7.5], 0.5 mM EDTA, 0.5% NP40, and 150
mM NaCl) in the presence of protease inhibitors (Roche Molecular
Biochemicals, Indianapolis, Indiana, United States). Equal amounts of
total proteins were immunoprecipitated with a-FLAG M2 agarose
(Sigma, St Louis, Missouri, United States), for 2 h at 4 8C.
Immunoprecipitated material was washed twice with IP buffer and
one time with SIRT deacetylation buffer (50 mM Tris-HCl [pH 9], 4
mM MgCl2, and 0.2 mM DTT). The beads were resuspended in 100 ll
of SIRT deacetylation buffer containing 1 lg synthetic Tat (72 amino
acids) carrying an N-terminal biotin label and an acetyl group at
position 50 [11]. Reactions containing TSA (400 nM; WACO
Bioproducts, Richmond, Virginia, United States) or nicotinamide (5
mM; Sigma) were preincubated for 10 min at room temperature.
After addition of NADþ (1 mM), reactions were incubated for 2 h at
room temperature with constant agitation. Reactions were stopped
by the addition of SDS loading buffer, boiled, and after brief
centrifugation, analyzed by WB with rabbit a-AcTat antibodies [11] or
SA-HRP (Jackson Immunoresearch Laboratories, West Grove, Penn-
sylvania, United States). SIRT1–7 proteins were detected with
polyclonal a-FLAG antibodies (Sigma).
The histone deacetylation assay with recombinant SIRT1 (1–1.3 U/
reaction; Biomol, Plymouth Meeting, Pennsylvania, United States) was
performed as described previously for SIRT2 [30] in 100 ll of SIRT
deacetylase buffer containing NADþ (Sigma) and enzymatically [3H]-
acetylated histone H3 peptide (amino acids 1–24) [62]. Splitomicin (a
gift from Julian Simon, Fred Hutchinson Cancer Research Center,
Seattle, Washington, United States) and HR73 in DMSO were added
to the reactions at the indicated concentrations with all components
of the reactions in the absence of NADþ for 10 min at room
temperature prior to the initiation of the reaction by addition of
NADþ (1 mM).
Coimmunoprecipitation experiments. HEK 293 cells were cotrans-
fected in duplicate with expression vectors for CMV-Tat/FLAG; CMV-
Tat/T7 or CMV-TatK50R/FLAG; and the SIRT1/HA or SIRT1-, SIRT2-,
and SIRT6-FLAG expression vectors or the respective empty vector
controls using Lipofectamine reagent (Invitrogen). Cells were lysed
after 24 h in 250 mM NaCl, 0.1% NP40, 20 mM NaH2PO4 (pH 7.5), 5
mM EDTA, 30 mM sodium pyrophosphate, 10 mM NaF, and protease
inhibitors (Roche Molecular Biochemicals). Duplicates were pooled,
and 1 mg of lysate was immunoprecipitated either with monoclonal
a-HA (Roche Molecular Biochemicals) together with protein G-
Sepharose (Amersham Biosciences, Piscataway, New Jersey, United
States) with a-FLAG M2 agarose (Sigma) or a-T7-agarose (Amersham
Biosciences) for 2 h at 4 8C. Beads were washed three times in lysis
buffer, boiled in SDS loading buffer, and analyzed by WB with
polyclonal a-FLAG (Sigma), monoclonal a-HA (Roche), or mono-
clonal a-T7 (Novagen, Madison, Wisconsin, United States) antibodies.
For the IP of Tat with endogenous SIRT1, HEK 293 cells were
transfected only with CMV-Tat/FLAG or the CMV-empty vector using
Lipofectamine reagent. Cell lysates were immunoprecipitated with
rabbit a-SIRT1 antibodies (generated against amino acids 506–747)
together with protein G-Sepharose (Amersham Biosciences). Immu-
noprecipitated material was analyzed by WB with the M2 a-FLAG
antibody (Sigma) or rabbit a-SIRT1 antibodies.
For in vitro interactions, 10 U of recombinant SIRT1 (Biomol) was
incubated with biotinylated synthetic Tat or acetylated Tat proteins
(0, 0.25, 1, and 4 lg) together with streptavidin-Sepharose (Amersham
Biosciences) in lysis buffer in the presence of 5 mM nicotinamide
(Sigma) for 3 h at 4 8C. Pelleted beads were washed three times in lysis
buffer, resuspended in SDS loading buffer, and analyzed by WB with
polyclonal a-SIRT1 antibodies, rabbit a-AcARM, or SA-HRP (Jackson
Immunoresearch Laboratories).
RNAi and transfection experiments. Double-stranded siRNAs
directed against nucleotides 408–428 in the SIRT1 mRNA or control
GL3 siRNAs (both Dharmacon Research, Lafayette, Colorado, United
States) were transfected into HeLa cells plated in six-well plates with
Oligofectamine reagent according to the manufacturer’s guidelines
(Invitrogen). The mutant SIRT1 siRNA was identical to SIRT1 siRNA
except for a two-nucleotide mismatch between the target mRNA for
SIRT1 and the antisense strand of siRNA at nucleotides 418 and 419.
After 48 h, cells were retransfected with the HIV LTR luciferase
construct (200 ng) together with increasing amounts of CMV-Tat
expression vectors (0, 50, 100, 200, 400, and 800 ng in GL3/SIRT1
siRNA experiments; 0, 2, 20, and 200 ng in SIRT1/mutant SIRT1
siRNA experiments) and corresponding amounts of empty pcDNA3.1
vector (Invitrogen). In the control experiment, CMV-Tat was replaced
by the CMV-luciferase construct, and HIV LTR luciferase was
replaced by an HIV LTR promoter construct driving the expression
of chloramphenicol acetyl transferase (CAT) [55]). Cells were
harvested 24 h later and either processed for luciferase assays
(Promega) or WB of total cell extracts with polyclonal a-SIRT1 or a-
actin (MP Biochemicals, Aurora, Ohio, United States) antibodies.
In cotransfection experiments, human CMV-SIRT1 or CMV-
SIRT1H363Y (600 ng) was cotransfected into HeLa cells plated in
six-well plates with the HIV LTR luciferase reporter (200 ng) or the
LTRDNF-jB-luciferase reporter (200 ng) and increasing amounts of
RSV-Tat (0, 2, 20, and 200 ng) using the Lipofectamine reagent
(Invitrogen). In the control experiment, RSV-Tat was replaced by
RSV-luciferase (200 ng), and the HIV LTR luciferase construct was
replaced by the HIV LTR CAT reporter. In transfections with HR73,
HeLa cells were cotransfected with the HIV LTR luciferase reporter
(200 ng) and RSV-Tat expression vectors (0, 20, and 200 ng) or the
empty vector using Lipofectamine reagent. The RSV-luciferase
construct was used as described above. After 4 h incubation with
the DNA/Lipofectamine mix, the culture medium was changed and
supplemented with indicated concentrations of HR73 dissolved in
DMSO or DMSO alone. Cells were harvested 8 h later and processed
for luciferase assays.
Microinjection experiments. Subconfluent MEFs (70%) were grown
on Cellocate coverslips (Eppendorf, Westbury, New York, United
States), and nuclear microinjections were performed at room
temperature with an automated injection system (Eppendorf Micro-
manipulator 5171 together with Eppendorf Transjector 5246).
Samples were prepared as a 20 ll injection mix containing the HIV
LTR luciferase reporter or 5xUAS luciferase (each 100 ng/ll), RSV-
Tat (10 ng/ll) or Gal4-VP16 (50 ng/ll), CMV-cyclinT1 (100 ng/ll),
CMV-SIRT1 (100 or 300 ng/ll), together with CMV-GFP (50 ng/ll) in
sterile water. At 6 h after microinjection, cells were examined under a
Nikon Eclipse TE300 inverted fluorescent microscope (Nikon, Tokyo,
Japan) to determine the number of GFP-positive cells, washed in cold
phosphate buffer, and stored at 70 8C for luciferase assays
(Promega). In HeLa cells, synthetic Tat or AcTat proteins (each 30
or 100 ng/ll) were coinjected with the wild-type or mutant HIV LTR
luciferase reporters (each 100 ng/ll) together with CMV-GFP (50 ng/
ll), and harvested 4 h after injection. Cells were treated immediately
after injection with DRB (10 or 50 lM; Sigma), TSA (400 nM), or
nicotinamide (5 mM). Microinjections in siRNA-treated cells were
performed 48 h after siRNA transfection.
Viral infection experiments. The HIV molecular clone HIV-R7/E/
GFP containing the GFP open reading frame in place of the nef gene
and a frameshift mutation in the env gene, as well as the method to
generate pseudotyped viral particles with VSV-G, were previously
described [43]. The number of infective particles per milliliter was
established by infecting 33 105 Jurkat cells with different amounts of
viral suspension. The titer of the viral stock was measured by flow
cytometric analysis of GFP expression 48 h after infection. The pHR9-
EF-1a/GFP construct is a minimal nonreplicative HIV-1 genome
containing a heterologous promoter, EF-1a, driving GFP expression
[63]. Viral particles were produced by cotransfection of the VSV-G-
encoding pMD.G and the HIV-based packaging vector pCMVDR8.91
as described [64]. All vectors for the production of HIV-based
lentiviral vectors were provided by Didier Trono, University of
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Geneva, Switzerland. Jurkat T cells were incubated overnight with
HIV-R7/E/GFP or pHR9-EF-1a/GFP viral particles at a theoretical
multiplicity of infection of 0.5 in 24-well plates. Cells were repeatedly
washed and resuspended in fresh medium containing HR73 (1 lM) or
DMSO alone. Viral infection was monitored 36 h later by flow
cytometry analysis using a Calibur FACScan (Becton Dickinson, Palo
Alto, California, United States).
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